

m (accessed 9 Aug 2010).

- Carelli F. Family medicine crisis? *Synapse Magazine* 2009; 12.

DOI: 10.3399/bjgp10X515485

Loch Eport

A few comments on Alec Logan's paragraph and photograph.¹ His latitude and longitude, I'm sure, are immaculate and the exquisite pink flowers are Thrift or Sea Pink (*Armeria maritima*), that grow in great profusion on the Hebridean coasts in summer. The loch pictured however, is Lochmaddy, not Locheport and the hill is Eaval, not Heaval, that every *BJGP* reader must know is on the island of Barra! I agree with nomenclature, that almost every hill in the Outer Hebrides has the Norse suffix -val (fjall or Fell). I was born and lived there, until I left for the first time aged 15 to further my schooling. I appreciate his kind remarks about my native isle and wish him many happy returns.

Alastair Morrison,
Sidinish, Ferntower Road, Crieff, PH7 3DH.
E-mail: gpmorrison@secaurazone.net

REFERENCE

- Logan A. Loch Eport. *Br J Gen Pract* 2010; **60**(576): 547.

DOI: 10.3399/bjgp10X515502

Smoking cessation

I read with interest the leader by Patrick White.¹ I share his enthusiasm for smoking cessation and pulmonary rehabilitation. I do not, however, share his enthusiasm for inhaler therapy beyond short-term beta-agonists. The evidence for long-term reductions in exacerbations and admissions is there but it is hardly striking. I do not think that we should extrapolate reductions in mortality until that evidence is there. The fact that it is not already, suggests that any reductions, sadly, won't be too great.

My concerns are that, once labelled the path of prescribing moves almost automatically to short-acting beta-agonists, long-acting beta-agonists, and inhaled steroids in all patients, even in those with mild disease and even in those with no objective or subjective hard evidence of improvement. How can we make treatment more objectively useful?

I do not want to be a therapeutic nihilist but equally this disease needs cost effective, evidence-based treatments that are re-assessed and stopped if they don't work. A huge sum is being spent promoting the benefits of multiple treatments, but rarely do these promotions emphasise, for instance, the increased pneumonias in people with chronic obstructive pulmonary disease who are being treated with inhaled steroids.

John Sharvill,
GP, Balmoral Surgery, Canada Road, Deal, Kent, CT14 7EQ.
E-mail: john.sharvill@nhs.net

REFERENCE

- White P. COPD in primary care: a time of opportunity. *Br J Gen Pract* 2010; **60**(576): 477-478.

DOI: 10.3399/bjgp10X515494

MMR and egg allergy: to vaccinate or not to vaccinate?

We do receive a number of referrals every year (10-15) from GPs for MMR to be administered in a hospital setting. The live measles and mumps vaccine is grown on cultured chick embryo fibroblasts and there is a concern that there could be some amount of egg protein in the vaccine. The controversy surrounding MMR and egg allergy has been long standing even though the hen's egg protein in the vaccine is highly processed and the concentrations are very low to trigger any allergic reaction.¹ There has

been a vast amount of evidence^{2,3} published already about the safety of MMR in children with egg allergy. In spite of various recommendations and guidelines, children are still being referred for MMR to be administered in a hospital setting.

The guidance in the UK surrounding MMR and egg allergy has changed over the years. The recommendations for MMR vaccine in egg allergic children were published in 2000.¹ It stated that children with mild egg allergy can be safely vaccinated in primary care and recommended that children with previous significant allergic reactions should be vaccinated in hospital. Most of our practice is still based on these recommendations.

The latest British Society of Allergy and Clinical Immunology (BSACI) guidance recommends that all children with egg allergy should be immunised in primary care. 'Children who have had documented anaphylaxis to the vaccine itself should be assessed by an allergist'.⁴

Our approach has always been to write back to GPs or to speak to them directly about the safety of MMR in egg allergy. We, however, do not know if any of these children did ever go on to have the vaccine in primary care.

We agree with the recommendation by Ainsworth *et al*⁵ of attaching a copy of BSACI guidelines when we write back to our GPs. Although the guidelines have been published, there is still a possibility that many of our colleagues in primary care are not aware of them. We believe that inclusion of these recommendations in all the immunisation leaflets and related websites would lead to increased awareness and reduce the confusion surrounding this controversy. We hope that the green book would include the same advice in its next edition.

Srinivas Bandi,
Consultant Paediatrician, University Hospital Coventry, Clifford Bridge Road, Coventry, CV2 2DX. E-mail: seenu_dr@hotmail.com

Colin MacDougall,
Consultant Paediatrician, University Hospital Coventry, Clifford Bridge Road, Coventry.